Drug Profile
Selpercatinib - Loxo oncology
Alternative Names: LOXO 292; LY-3527723; RETEVMO; RetsevmoLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Eli Lilly and Company; Loxo Oncology
- Class Antineoplastics; Aza compounds; Ethers; Nitriles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Proto oncogene protein c ret inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Phase I/II CNS cancer
Most Recent Events
- 18 Jan 2024 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 31 Oct 2023 Eli Lilly and Company completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT05906836)
- 21 Oct 2023 Efficacy data from a phase III LIBRETTO-431 trial in Non-small cell lung cancer released by Eli Lilly and Company